Akili Interactive Labs Inc. has expanded its series B financing with an additional $11.9m from new investors Merck Ventures BV, Amsterdam, the Netherlands, a subsidiary of Merck KGAA , and Amgen Ventures, the venture arm of Amgen Inc.
Earlier this year, Akili raised $30.5m from investors including JAZZ Venture Partners, Canepa Advanced Healthcare Fund and PureTech totaling the series B round to $42.4m. (Also see " Pharma...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?